Some antihistamines, mainly first-generation products, may cause urinary retention in patients with benign prostatic hypertrophy (BPH). This is due to an interaction with muscarinic receptors and as a result of poor receptor selectivity. Bilastine has not been studied in a subgroup of subjects with a diagnosis of BPH with urinary retention and/or dysuria. Nevertheless, based on its receptor-selectivity profile, which was clearly established in preclinical studies, and the results from which are included in the SmPC section 5.1 (pharmacological properties) ‘without affinity for muscarinic receptors’, it seems reasonable to think that bilastine will not increase the risk of urinary retention/dysuria.
